Related Experiment Video
Updated: Sep 28, 2025

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
Published on: June 29, 2022
Honokiol Inhibits Atrial Metabolic Remodeling in Atrial Fibrillation Through Sirt3 Pathway
Guang Zhong Liu1,2, Wei Xu3, Yan Xiang Zang3
1Department of Cardiology, Shenzhen Cardiovascular Minimally Invasive Medical Engineering Technology Research and Development Center, Shenzhen People's Hospital, Shenzhen, China.
Insights
Honokiol (HL) reversed atrial metabolic remodeling in atrial fibrillation (AF) by activating Sirtuin3 (Sirt3). This study suggests HL as a potential therapeutic strategy for AF by restoring energy homeostasis.
Area of Science:
- Cardiovascular Research
- Metabolic Pathways
- Molecular Biology
Background:
- Atrial metabolic remodeling is a key factor in atrial fibrillation (AF) development.
- Sirtuin3 (Sirt3) is crucial for maintaining cellular energy balance.
- The therapeutic potential of the Sirtuin3 agonist Honokiol (HL) in AF remains largely unexplored.
Purpose of the Study:
- To investigate the impact of Honokiol (HL) on atrial metabolic remodeling in the context of atrial fibrillation (AF).
- To elucidate the underlying mechanisms by which HL influences AF pathophysiology, particularly concerning Sirtuin3 (Sirt3) activity.
Main Methods:
- Analysis of Sirt3 and glycogen in atrial tissues from AF patients and a rabbit pacing model.
- In vitro experiments using HL-1 cells subjected to rapid pacing, with or without HL treatment and Sirt3 modulation.
- Assessment of metabolic factors, circulating metabolites, atrial electrophysiology, ATP levels, glycogen deposition, and protein acetylation.
Main Results:
- Sirt3 was downregulated in AF, and HL treatment restored its expression and downstream metabolic factors.
- AF increased acetylation of key metabolic enzymes (LCAD, AceCS2, GDH), reducing their activity and ATP levels; HL inhibited these effects.
- Sirt3 activation by HL mitigated AF-induced atrial metabolic remodeling and restored metabolic homeostasis.
Conclusions:
- Honokiol (HL) effectively inhibits atrial metabolic remodeling in AF through the Sirtuin3 (Sirt3) pathway.
- HL demonstrates potential as a novel therapeutic agent for managing atrial fibrillation (AF).
Abstract:
Background and Purpose: Atrial metabolic remodeling plays a critical role in the pathogenesis of atrial fibrillation (AF). Sirtuin3 (Sirt3) plays an important role in energy homeostasis. However, the effect of Sirt3 agonist Honokiol (HL) on AF is unclear. Therefore, the aim of this study is to determine the effect of HL on atrial metabolic remodeling in AF and to explore possible mechanisms. Experimental Approach: irt3 and glycogen deposition in left atria of AF patients were examined. Twenty-one rabbits were divided into sham, P (pacing for 3 weeks), P + H treatment (honokiol injected with pacing for 3 weeks). The HL-1 cells were subjected to rapid pacing at 5 Hz for 24 h, in the presence or absence of HL and overexpression or siRNA of Sirt3 by transfection. Metabolic factors, circulating metabolites, atrial electrophysiology, ATP level, and glycogens deposition were detected. Acetylated protein and activity of its enzymes were detected. Key Results: Sirt3 was significantly down-regulated in AF patients and rabbit/HL-1cell model, resulting in the abnormal expression of its downstream metabolic key factors, which were significantly restored by HL. Meanwhile, AF induced an increase of the acetylation level in long-chain acyl-CoA dehydrogenase (LCAD), AceCS2 and GDH, following decreasing of activity of it enzymes, resulting in abnormal alterations of metabolites and reducing of ATP, which was inhibited by HL. The Sirt3 could regulate acetylated modification of key metabolic enzymes, and the increase of Sirt3 rescued AF induced atrial metabolic remodeling. Conclusion and Implications: HL inhibited atrial metabolic remodeling in AF via the Sirt3 pathway. The present study may provide a novel therapeutical strategy for AF.
More Related Videos
08:31Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
10:53Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Atherosclerosis III: Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Regulation of Heart Rates
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
Mechanism of Cardiac Arrhythmias